WallStSmart

Aquestive Therapeutics Inc (AQST)vsUnited Therapeutics Corporation (UTHR)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 6427% more annual revenue ($3.19B vs $48.84M). UTHR leads profitability with a 38.6% profit margin vs -162.3%. UTHR earns a higher WallStSmart Score of 55/100 (C).

AQST

Avoid

18

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: -4.23

UTHR

Buy

55

out of 100

Grade: C

Growth: 4.7Profit: 9.0Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 8.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AQSTSignificantly Overvalued (-52.8%)

Margin of Safety

-52.8%

Fair Value

$2.50

Current Price

$3.46

$0.96 premium

UndervaluedFair: $2.50Overvalued
UTHRUndervalued (+2.4%)

Margin of Safety

+2.4%

Fair Value

$487.77

Current Price

$554.73

$66.96 discount

UndervaluedFair: $487.77Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AQST1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.1110/10

Conservative balance sheet, low leverage

UTHR3 strengths · Avg: 9.3/10
Profit MarginProfitability
38.6%10/10

Keeps 39 of every $100 in revenue as profit

Altman Z-ScoreHealth
8.5610/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.0%8/10

Strong operational efficiency at 29.0%

Areas to Watch

AQST4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$491.44M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

UTHR3 concerns · Avg: 3.3/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

EPS GrowthGrowth
-20.3%2/10

Earnings declined 20.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AQST

The strongest argument for AQST centers on Debt/Equity.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Altman Z-Score, Operating Margin. Profitability is solid with margins at 38.6% and operating margin at 29.0%.

Bear Case : AQST

The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

AQST profiles as a turnaround stock while UTHR is a value play — different risk/reward profiles.

AQST carries more volatility with a beta of 1.50 — expect wider price swings.

UTHR is growing revenue faster at 4.1% — sustainability is the question.

UTHR generates stronger free cash flow (126M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (55/100 vs 18/100), backed by strong 38.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aquestive Therapeutics Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?